Directorio

We are doing this study to find the most effective, safe dose of an experimental drug called IAM1363 (the study drug) for people who have advanced cancers harboring HER2 alterations.

This study is a biorepository (storehouse) where samples and data from critically ill patients with COVID-19 are stored. The reason for this study is to develop a collection of samples and data that can be shared with other doctors and researchers to help them answer important questions about the virus and possibly help develop treatments and tests for the future. Este estudio es un registro central para guardar información y muestras de pacientes críticamente enfermos en una Unidad de Cuidados Intensivos (ICU) que tienen COVID-19 El objetivo de este estudio es crear una colección de información y muestras que pueda ser compartida con otros médicos y otros investigadores para ayudar a responder preguntas importantes sobre el virus, y posiblemente desarrollar tratamientos y pruebas de detección en el futuro.

Study visits at week 0, 4, 6, 8, and 12

This study is being done to learn more about a vision problem called age related macular degeneration. It focuses on a late stage form called geographic atrophy, which can slowly damage vision. Researchers will follow people for at least six months and do tests to see how their vision changes over time. They will also look at genes, inflammation in the body, and lifestyle factors to see if these are linked to how the disease gets better or worse. The goal is to better understand this condition and help improve care in the future.

We are doing this study to learn more about how different factors affect people with two types of dry eye conditions: Sjögren's dry eye (SjD) and non-Sjögren's dry eye. Specifically, we want to know how neurotrophic keratitis (a condition where the cornea loses sensation) versus the severity of tear film and eye surface issues impact the structure and function of the cornea (the clear front part of the eye). We also want to find out if having dry eyes leads to less feeling in the cornea, and if this reduced feeling is linked to eye pain or pain in other parts of the body.

We are doing this study to compare the outcomes of people who get their after-transplant care in the hospital versus in their home. This study is important to learn if getting after-transplant care in a patient's home can lead to better outcomes.